U.S. Veterinary Diagnostics Market – Industry Trends and Forecast to 2030

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

U.S. Veterinary Diagnostics Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Upcoming Report
  • Mar 2023
  • Country Level
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF U.S. VETERINARY DIAGNOSTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL XX SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 U.S. VETERINARY DIAGNOSTICS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 INNOVATION STRATEGIES AND METHODOLOGIES

10.3 RISK ASSESSMENT AND MITIGATION

10.4 FUTURE OUTLOOK

11 REGULATORY COMPLIANCE

11.1 REGULATORY AUTHORITIES

11.2 REGULATORY CLASSIFICATIONS

11.2.1 CLASS I

11.2.2 CLASS II

11.2.3 CLASS III

11.3 REGULATORY SUBMISSIONS

11.4 INTERNATIONAL HARMONIZATION

11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

11.6 REGULATORY CHALLENGES AND STRATEGIES

12 VALUE CHAIN ANALYSIS

12.1 ECONOMIC DEVELOPMENT

13 U.S. VETERINARY DIAGNOSTICS MARKET, BY PRODUCT

13.1 OVERVIEW

13.2 INTRUMENTS & DEVICES

13.2.1 BY TYPE

13.2.1.1. IMAGING DEVICES

13.2.1.1.1. SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)

13.2.1.1.2. X-RAY IMAGING (RADIOGRAPHY)

13.2.1.1.3. ULTRASOUND

13.2.1.1.4. COMPUTED TOMOGRAPHY

13.2.1.1.5. MAGNETIC RESONANCE IMAGING

13.2.1.1.6. OTHERS

13.2.1.2. LABORATORY INSTRUMENTS

13.2.1.2.1. HEMATOLOGY ANALYZERS

13.2.1.2.2. CHEMISTRY ANALYZERS

13.2.1.2.3. COAGULATION ANALYZERS

13.2.1.2.4. REFRACTOMETER

13.2.1.2.5. URINALYSIS EQUIPMENT

13.2.1.3. POINT-OF-CARE INSTRUMENTS

13.2.1.3.1. LATERAL FLOW POCT

13.2.1.3.2. MOLECULAR POCT

13.2.1.3.3. OTHERS

13.2.1.4. OTHERS

13.2.2 BY MODALITY

13.2.2.1. BENCHTOP

13.2.2.2. STANDALONE

13.2.2.3. PORTABLE

13.2.3 BY FUNCTION

13.2.3.1. AUTOMATED

13.2.3.2. SEMIAUTOMATED

13.2.3.3. MANUAL

13.3 REAGENTS & CONSUMBALES

13.3.1 KITS

13.3.1.1. ELISA KITS

13.3.1.1.1. PCR KITS

13.3.1.1.2. MULTPLEX KITS

13.3.1.1.3. RAPID TEST KITS

13.3.1.1.4. SAMPLE PREPARATION KITSISOLATION AND EXTRACTION KITS

13.3.1.1.5. OTHERS

13.3.2 REAGENTS

13.3.2.1. IMMUNOFLUORESCENCE REAGENTS

13.3.2.1.1. INDIRECT IMMUNOFLUORESCENCE

13.3.2.1.2. DIRECT IMMUNOFLUORESCENCE

13.3.2.2. COOMBS REAGENTS

13.3.2.3. NUCLEIC ACID EXTRACTION REAGENTS

13.3.2.4. OTHERS REAGENTS

13.3.3 CASSETTE

13.3.4 STRIPS

13.3.5 PANEL

13.3.6 CONTROL STANDARDS

13.3.7 PROBES AND PRIMER

13.3.8 MEDIA

13.3.9 OTHERS CONSUBAME AND ACCESSORIES

14 U.S. VETERINARY DIAGNOSTICS MARKET, BY TECHNOLOGY

14.1 OVERVIEW

14.2 IMMUNODIAGNOSTICS

14.2.1 BY TYPE

14.2.1.1. ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS)

14.2.1.2. RADIOIMMUNOASSAYS

14.2.1.3. IMMUNOFLUORESCENCE

14.2.1.4. OTHERS

14.2.2 BY ANIMAL TYPE

14.2.2.1. COMPANION ANIMAL

14.2.2.2. LIVESTOCK ANIMALS

14.3 MOLECULAR DIAGNOSTICS

14.3.1 BY TYPE

14.3.1.1. POLYMERASE CHAIN REACTION (PCR)

14.3.1.1.1. SPCR

14.3.1.1.2. QPCR

14.3.1.1.3. RT-PCR

14.3.1.1.4. MULTIPLEX PCR

14.3.1.1.5. OTHERS

14.3.1.2. MICROARRAY

14.3.1.3. DNA SEQUENCING

14.3.1.3.1. SANGER SEQUENCING

14.3.1.3.2. FRAGMENT SEQUENCING

14.3.1.3.3. NEXT-GENERATION SEQUENCING (NGS)

14.3.1.3.4. OTHERS

14.3.1.4. OTHERS

14.3.2 BY ANIMAL TYPE

14.3.2.1. COMPANION ANIMAL

14.3.2.2. LIVESTOCK ANIMALS

14.4 HAEMATOLOGY

14.4.1 BY ANIMAL TYPE

14.4.1.1. COMPANION ANIMAL

14.4.1.2. LIVESTOCK ANIMALS

14.5 URINALYSIS

14.5.1 BY ANIMAL TYPE

14.5.1.1. COMPANION ANIMAL

14.5.1.2. LIVESTOCK ANIMALS

14.6 CLINICAL BIOCHEMISTRY

14.6.1 BY ANIMAL TYPE

14.6.1.1. COMPANION ANIMAL

14.6.1.2. LIVESTOCK ANIMALS

14.7 IMAGING

14.7.1 BY ANIMAL TYPE

14.7.1.1. COMPANION ANIMAL

14.7.1.2. LIVESTOCK ANIMALS

14.8 OTHERS

15 GLOBAL VETERINARY DIAGNOSTICS MARKET, BY ANIMAL TYPE

15.1 OVERVIEW

15.2 COMPANION ANIMALS

15.2.1 DOGS

15.2.2 CATS

15.2.3 HORSES

15.2.4 OTHER

15.3 LIVESTOCK ANIMAL

15.3.1 CATTLE

15.3.2 SWINE

15.3.3 POULTRY

15.3.4 OTHER

16 U.S. VETERINARY DIAGNOSTICS MARKET, BY DISEASE TYPE

16.1 OVERVIEW

16.2 INFECTIOUS DISEASES

16.2.1 BACTERIAL

16.2.1.1. CANINE PYOMETRA

16.2.1.2. ACTINOBACILLOSIS

16.2.1.3. ACTINOMYCOSIS

16.2.1.4. OTHERS

16.2.2 VIRAL

16.2.2.1. CANINE PARVOVIRUS

16.2.2.2. BOVINE VIRAL DIARRHEA (BVD)

16.2.2.3. OTHERS

16.2.3 FUNGAL

16.2.3.1. RINGWORM

16.2.3.2. CRYPTOCOCCOSIS

16.2.4 OTHERS

16.3 NON-INFECTIOUS DISEASES

16.3.1 CUSHING'S DISEASE

16.3.2 DIABETES MELLITUS

16.3.3 RENAL (KIDNEY) DISEASE

16.3.4 OTHERS

16.4 HEREDITARY

16.4.1 CANCER

16.4.2 HEART DISEASE

16.4.3 SKIN COMPLAINTS

16.4.4 EPILEPSY

16.4.5 HIP DYSPLASIA

16.4.6 OTHERS

16.5 OTHERS

17 U.S. VETERINARY DIAGNOSTICS MARKET, BY TESTING LOCATION

17.1 OVERVIEW

17.2 LABORATORIES BASED TESTING

17.3 POINT OF CARE TESTING

18 U.S. VETERINARY DIAGNOSTICS MARKET, BY END USER

18.1 OVERVIEW

18.2 VETERINARY HOSPITAL

18.3 VETERINARY CLINICS

18.4 ANIAML FARMS AND HUSBANDRY

18.5 PET SHOPS

18.6 ACAMEIC AND RESEARCH LABORATORIES

18.7 OTHER

19 U.S. VETERINARY DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

19.1 OVERVIEW

19.2 DIRECT TENDER

19.3 RETAIL SALES

19.4 ONLINE SALES

19.5 OTHERS

20 U.S. VETERINARY DIAGNOSTICS MARKET, BY GEOGRAPHY

U.S. VETERINARY DIAGNOSTICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

21 U.S. VETERINARY DIAGNOSTICS MARKET, COMPANY LANDSCAPE

21.1 COMPANY SHARE ANALYSIS: U.S.

21.2 MERGERS & ACQUISITIONS

21.3 NEW PRODUCT DEVELOPMENT & APPROVALS

21.4 EXPANSIONS

21.5 REGULATORY CHANGES

21.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

22 U.S. VETERINARY DIAGNOSTICS MARKET, SWOT ANALYSIS

23 U.S. VETERINARY DIAGNOSTICS MARKET, COMPANY PROFILE

23.1 IDEXX

23.1.1 COMPANY OVERVIEW

23.1.2 REVENUE ANALYSIS

23.1.3 GEOGRAPHIC PRESENCE

23.1.4 PRODUCT PORTFOLIO

23.1.5 RECENT DEVELOPMENTS

23.2 ZOETIS SERVICES LLC

23.2.1 COMPANY OVERVIEW

23.2.2 REVENUE ANALYSIS

23.2.3 GEOGRAPHIC PRESENCE

23.2.4 PRODUCT PORTFOLIO

23.2.5 RECENT DEVELOPMENTS

23.3 THERMO FISHER SCIENTIFIC INC

23.3.1 COMPANY OVERVIEW

23.3.2 REVENUE ANALYSIS

23.3.3 GEOGRAPHIC PRESENCE

23.3.4 PRODUCT PORTFOLIO

23.3.5 RECENT DEVELOPMENTS

23.4 HESKA CORPORATION

23.4.1 COMPANY OVERVIEW

23.4.2 REVENUE ANALYSIS

23.4.3 GEOGRAPHIC PRESENCE

23.4.4 PRODUCT PORTFOLIO

23.4.5 RECENT DEVELOPMENTS

23.5 NEOGEN CORPORATION

23.5.1 COMPANY OVERVIEW

23.5.2 REVENUE ANALYSIS

23.5.3 GEOGRAPHIC PRESENCE

23.5.4 PRODUCT PORTFOLIO

23.5.5 RECENT DEVELOPMENTS

23.6 BIO-RAD LABORATORIES, INC.

23.6.1 COMPANY OVERVIEW

23.6.2 GEOGRAPHIC PRESENCE

23.6.3 PRODUCT PORTFOLIO

23.6.4 RECENT DEVELOPMENTS

23.7 VIRBAC

23.7.1 COMPANY OVERVIEW

23.7.2 REVENUE ANALYSIS

23.7.3 GEOGRAPHIC PRESENCE

23.7.4 PRODUCT PORTFOLIO

23.7.5 RECENT DEVELOPMENTS

23.8 BIONOTE USA INC.

23.8.1 COMPANY OVERVIEW

23.8.2 REVENUE ANALYSIS

23.8.3 GEOGRAPHIC PRESENCE

23.8.4 PRODUCT PORTFOLIO

23.8.5 RECENT DEVELOPMENTS

23.9 EUROFINS SCIENTIFIC.

23.9.1 COMPANY OVERVIEW

23.9.2 REVENUE ANALYSIS

23.9.3 GEOGRAPHIC PRESENCE

23.9.4 PRODUCT PORTFOLIO

23.9.5 RECENT DEVELOPMENTS

23.1 VMRD, INC.

23.10.1 COMPANY OVERVIEW

23.10.2 GEOGRAPHIC PRESENCE

23.10.3 PRODUCT PORTFOLIO

23.10.4 RECENT DEVELOPMENTS

23.11 FUJIFILM

23.11.1 COMPANY OVERVIEW

23.11.2 REVENUE ANALYSIS

23.11.3 GEOGRAPHIC PRESENCE

23.11.4 PRODUCT PORTFOLIO

23.11.5 RECENT DEVELOPMENTS

23.12 MINDRAY ANIMAL MEDICAL TECHNOLOGY NORTH AMERICA CO., LTD.

23.12.1 COMPANY OVERVIEW

23.12.2 REVENUE ANALYSIS

23.12.3 GEOGRAPHIC PRESENCE

23.12.4 PRODUCT PORTFOLIO

23.12.5 RECENT DEVELOPMENTS

23.13 ESAOTE SPA

23.13.1 COMPANY OVERVIEW

23.13.2 REVENUE ANALYSIS

23.13.3 GEOGRAPHIC PRESENCE

23.13.4 PRODUCT PORTFOLIO

23.13.5 RECENT DEVELOPMENTS

23.14 PLANMECA

23.14.1 COMPANY OVERVIEW

23.14.2 REVENUE ANALYSIS

23.14.3 GEOGRAPHIC PRESENCE

23.14.4 PRODUCT PORTFOLIO

23.14.5 RECENT DEVELOPMENTS

24 RELATED REPORTS

25 QUESTIONNAIRE

26 ABOUT DATA BRIDGE MARKET RESEARCH